基于TCGA数据库分析非小细胞肺癌SERPINA1、FHIT甲基化水平及临床意义
收稿日期: 2020-06-10
网络出版日期: 2022-07-26
基金资助
国家重点研发计划课题(2018YFC 1311900);国家自然科学基金项目(81770084);国家自然科学基金项目(81570082);上海市重中之重临床医学中心和重点学科建设计划项目(2017ZZ02014);上海市科学技术委员会科研计划项目(18140903600)
The magnitude and clinical implication of SERPINA1 and FHIT methylation in non-small cell lung cancer based on analysis of TCGA database
Received date: 2020-06-10
Online published: 2022-07-26
目的：基于TCGA数据库的肺腺癌、肺鳞癌临床数据及甲基化数据,分析非小细胞肺癌（non-small cell lung cancer, NSCLC）患者丝氨酸蛋白酶抑制剂家族A成员1（serine protease inhibitor A1, SERPINA1）、脆性组氨酸三联体（fragile histidine triad,FHIT）基因的甲基化特征。方法：通过TCGA数据库在线和下载分析肺腺癌、肺鳞癌的临床数据和肿瘤组织SERPINA1、FHIT基因的mRNA和甲基化数据,探讨SERPINA1、FHIT甲基化与患者临床病理特征的相关性。结果：肺腺癌和肺鳞癌中的SERPINA1表达水平均低于癌旁对照组织。男性肺腺癌患者肿瘤组织SERPINA1甲基化水平低于女性腺癌患者（P<0.05）。有转移的肺腺癌患者的癌组织SERPINA1较无转移的肺腺癌患者呈低甲基化（P<0.05）。未发现SERPINA1、FHIT甲基化与吸烟史、TNM分期和总生存期存在相关性。结论：SERPINA1和FHIT甲基化可能参与肺癌发生、发展,NSCLC患者SERPINA1低甲基化与肿瘤转移相关。
王佳卉, 李宁, 孙娴雯, 林莹妮, 丁永杰, 宋鹤杰, 李庆云 . 基于TCGA数据库分析非小细胞肺癌SERPINA1、FHIT甲基化水平及临床意义[J]. 内科理论与实践, 2021 , 16(02) : 103 -107 . DOI: 10.16138/j.1673-6087.2021.02.008
Objective To investigate the significance of serine protease inhibitor A1 (SERPINA1) and fragile histidine triad(FHIT) methylation in non-small cell lung cancer(NSCLC) patients based on analysis of TCGA database. Methods The information of SERPINA1/FHIT gene expression, methylation information and associated clinical manifestations were retrieved from TCGA database and analyzed both online and offline. The link between the magnitude of SERPINA1 and FHIT methylation and parameters, such as age, gender, histological-type, smoking history and TNM stage, was probed. Results The expression level of SERPINA1 was higher in tumor tissues other than adjacent non-tumor lung tissues in both lung adenocarcinoma (LUAD) and lung squamous-cell cancer (LUSC) (P<0.05). Hypomethylation of SERPINA1 was mostly observed in LUAD tissue of male patients or individuals with metastasis(P<0.05). The methylation of SERPINA1 and FHIT methylation was not affected by smoking history, nor was it associated with TNM stage or overall survival. Conclusions SERPINA1 and FHIT methylation might play a role in lung cancer. Hypomethylation in SERPINA1 is related with metastasis of LUAD.
| [1] | 孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2019, 28(1): 1-11. |
| [2] | Mouronte-Roibás C, Leiro-Fernández V, Ruano-Raviña A, et al. Predictive value of a series of inflammatory markers in COPD for lung cancer diagnosis: a case-control study[J]. Respir Res, 2019, 20(1): 198. |
| [3] | Silveira Zavalhia L, Weber Medeiros A, Oliveira Silva A, et al. Do FHIT gene alterations play a role in human solid tumors[J]?. Asia Pac J Clin Oncol, 2018, 14(5): e214-e223. |
| [4] | Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-W102. |
| [5] | Samur MK. RTCGAToolbox: a new tool for exporting TCGA Firehose data[J]. PLoS One, 2014, 9(9): e106397. |
| [6] | Koch A, De Meyer T, Jeschke J, et al. MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data[J]. BMC Genomics, 2015, 16(1): 636. |
| [7] | Esteller M. Epigenetics in cancer[J]. N Engl J Med, 2008, 358(11): 1148-1159. |
| [8] | 罗汶鑫, 李为民. 肺癌的表观遗传学研究进展及其临床意义[J]. 中国呼吸与危重监护杂志, 2018, 17(3): 313-318. |
| [9] | Portela A, Esteller M. Epigenetic modifications and human disease[J]. Nat Biotechnol, 2010, 28(10): 1057-1068. |
| [10] | Selamat SA, Galler JS, Joshi AD, et al. DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma[J]. PLoS One, 2011, 6(6): e21443. |
| [11] | El-Akawi ZJ, Abu-Awad AM, Sharara AM, et al. The importance of alpha-1 antitrypsin (α-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients[J]. Neuro Endocrinol Lett, 2010, 31(1): 113-116. |
| [12] | Qiu W, Baccarelli A, Carey VJ, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function[J]. Am J Respir Crit Care Med, 2012, 185(4): 373-381. |
| [13] | Jaberie H, Hosseini SV, Naghibalhossaini F. Evaluation of alpha 1-antitrypsin for the early diagnosis of colorectal cancer[J]. Pathol Oncol Res, 2020, 26(2): 1165-1173. |
| [14] | Frenzel E, Wrenger S, Brügger B, et al. α1-Antitrypsin combines with plasma fatty acids and induces angiopoietin-like protein 4 expression[J]. J Immunol, 2015, 195(8): 3605-3616. |
| [15] | Ercetin E, Richtmann S, Delgado BM, et al. Clinical significance of SERPINA1 gene and its encoded alpha1-antitrypsin protein in NSCLC[J]. Cancers (Basel), 2019, 11(9): 1306. |
| [16] | Song X, Tian Z, Wang S, et al. Restoration of fragile histidine triad(FHIT) expression inhibits cell growth and induces apoptosis in cutaneous T-cell lymphoma cell line[J]. Cancer Invest, 2010, 28(10): 1019-1023. |
| [17] | Czarnecka KH, Migdalska-Sęk M, Domańska D, et al. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer[J]. Int J Oncol, 2016, 49(3): 1175-1184. |
| [18] | Wu X, Wu G, Yao X, et al. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review[J]. Drug Des Devel Ther, 2016, 10: 699-709. |
| [19] | Geradts J, Fong KM, Zimmerman PV, et al. Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features[J]. Br J Cancer, 2000, 82(6): 1191-1197. |
| [20] | de Fraipont F, Moro-Sibilot D, Michelland S, et al. Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer[J]?. Lung Cancer, 2005, 50(2): 199-209. |
| [21] | Maruyama R, Sugio K, Yoshino I, et al. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma[J]. Cancer, 2004, 100(7): 1472-1477. |
/
| 〈 |
|
〉 |
